Adopt a pro-innovation regulatory and trade agenda
Preserve the uniquely American system that balances incentives for innovation with affordability by protecting intellectual property at home and abroad, modernizing the FDA to keep pace with innovation, defending American workers and limiting foreign free-riding through strong trade agreements.

Protect the United States from the harms of price setting
Protect patients, pharmacists and providers from the harms of price setting policies that undermine innovation and create new access barriers for American patients.

Fix the IRA’s pill penalty to allow all medicines to compete for 13 years before eligibility for government price setting and prevent further expansion of price setting to maintain patient choice of medicines.

Stop the abuse in the 340B hospital markup program
Pursue comprehensive reform that prevents abuse and ensures the 340B program lowers medicine costs for low-income patients.

Do not stand in the way of private market solutions that would ensure program compliance and limit illegal activity.

Rein in the middlemen to put patients over PBM profits
Stop PBM practices that are driving up costs and limiting access for patients by sharing savings negotiated between manufacturers and PBMs directly to patients, delinking PBM compensation from the list price of medicine, ensuring patients benefit from manufacturer assistance programs and holding health plans accountable for providing patient care.